Literature DB >> 19438595

Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia.

I M E Desar1, M van Deuren, T Sprong, J B M J Jansen, F Namavar, C M Vandenbroucke-Grauls, J W M van der Meer.   

Abstract

The two major primary antibody deficiency disorders are X-linked hypogammaglobulinaemia (XLA) and common variable immunodeficiency (CVID). CVID patients have an elevated risk for gastric cancer and extra-nodal marginal zone lymphoma. Both diseases are associated with Helicobacter pylori infection. We investigated whether antibody deficiency leads to defective serum bactericidal activity against H. pylori. We also investigated the correlation with immunoglobulin (Ig)M levels and observed the terminal complement complex (TCC) activity. Sera of 13 CVID patients (four H. pylori positive), one patient with hyper-IgM syndrome, one patient with Good syndrome (both H. pylori positive), five XLA patients, four H. pylori seropositive controls, four H. pylori seronegative controls and a sample of pooled human serum (PHS) were incubated in vitro with bacterial suspensions of H. pylori for 30 min. After 72 h of culture, colony-forming units were counted. TCC formation was measured by enzyme-linked immunosorbent assay. We found that normal human serum is bactericidal for H. pylori, whereas heat-inactivated serum shows hardly any killing of H. pylori. Serum (1%) of hypogammaglobulinaemia patients has a decreased bactericidal activity against H. pylori. Helicobacter pylori-positive (HP(+)) normal individuals show more than 90% killing of H. pylori, whereas CVID patients show 35% killing (P = 0.007) and XLA patients only 19% (P = 0.003). Serum (1%) of HP(+) volunteers showed significantly better killing compared with serum of H. pylori-negative (HP(-)) volunteers (P = 0.034). No correlation between (substituted) IgG levels and serum bactericidal activity was found, but a weak correlation between total serum IgM and serum bactericidal activity was found. In conclusion, serum bactericidal activity against H. pylori is decreased in patients with hypogammaglobulinaemia. Heat treatment of the serum abolished the bactericidal capacity, indicating that complement activity is essential for the bactericidal effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438595      PMCID: PMC2691971          DOI: 10.1111/j.1365-2249.2009.03909.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.

Authors:  Tom Sprong; Petter Brandtzaeg; Michael Fung; Anne M Pharo; E Arne Høiby; Terje E Michaelsen; Audun Aase; Jos W M van der Meer; Marcel van Deuren; Tom E Mollnes
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

2.  Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes.

Authors:  M-A Alyanakian; E Bernatowska; J-M Scherrmann; P Aucouturier; J-L Poplavsky
Journal:  Vox Sang       Date:  2003-04       Impact factor: 2.144

3.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

4.  Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis.

Authors:  Olga Hegedus; Johan Rydén; Ann-Sofie Rehnberg; Stefan Nilsson; Per M Hellström
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-05       Impact factor: 2.566

5.  Complement activation directly induced by Helicobacter pylori.

Authors:  A E Berstad; K Høgåsen; G Bukholm; A P Moran; P Brandtzaeg
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

6.  Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study.

Authors:  L Mellemkjaer; L Hammarstrom; V Andersen; J Yuen; C Heilmann; T Barington; J Bjorkander; J H Olsen
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

7.  Hypogammaglobulinaemia: cumulative experience in 49 patients in a tertiary care institution.

Authors:  J C H Van der Hilst; B W Smits; J W M van der Meer
Journal:  Neth J Med       Date:  2002-04       Impact factor: 1.422

Review 8.  Common variable immunodeficiency: a new look at an old disease.

Authors:  Miguel A Park; James T Li; John B Hagan; Daniel E Maddox; Roshini S Abraham
Journal:  Lancet       Date:  2008-08-09       Impact factor: 79.321

9.  Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity.

Authors:  M Drogari-Apiranthitou; E J Kuijper; N Dekker; J Dankert
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

10.  Assessment of thymic output in common variable immunodeficiency patients by evaluation of T cell receptor excision circles.

Authors:  V Guazzi; F Aiuti; I Mezzaroma; F Mazzetta; G Andolfi; A Mortellaro; M Pierdominici; R Fantini; M Marziali; A Aiuti
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

View more
  10 in total

Review 1.  Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature.

Authors:  Antonio Pecoraro; Liliana Nappi; Ludovica Crescenzi; Francesco P D'Armiento; Arturo Genovese; Giuseppe Spadaro
Journal:  J Clin Immunol       Date:  2017-11-14       Impact factor: 8.317

Review 2.  Gastric adenocarcinoma in the context of X-linked agammaglobulinemia: case report and review of the literature.

Authors:  Aidé Tamara Staines Boone; María Guadalupe Torres Martínez; Gabriela López Herrera; Julia O de Leija Portilla; Sara Elva Espinosa Padilla; Francisco J Espinosa Rosales; Saúl Oswaldo Lugo Reyes
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 3.  Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme.

Authors:  F Dhalla; S P da Silva; M Lucas; S Travis; H Chapel
Journal:  Clin Exp Immunol       Date:  2011-04-06       Impact factor: 4.330

Review 4.  Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD).

Authors:  Mathieu Uzzan; Huaibin M Ko; Saurabh Mehandru; Charlotte Cunningham-Rundles
Journal:  Curr Gastroenterol Rep       Date:  2016-04

Review 5.  Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia.

Authors:  Stuart E Turvey; Sara H Leo; Annette Boos; Gregory D Deans; Julie Prendiville; Richard I Crawford; Christof Senger; Mary Ellen Conley; Peter Tilley; Anne Junker; Loretta Janz; Robert Azana; Linda Hoang; Tracy L Morton
Journal:  J Clin Immunol       Date:  2012-07-28       Impact factor: 8.317

Review 6.  Campylobacter jejuni bacteremia and Helicobacter pylori in a patient with X-linked agammaglobulinemia.

Authors:  T van den Bruele; P E C Mourad-Baars; E C J Claas; R N van der Plas; E J Kuijper; R G M Bredius
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-17       Impact factor: 3.267

7.  CD40 Ligand Deficient C57BL/6 Mouse Is a Potential Surrogate Model of Human X-Linked Hyper IgM (X-HIGM) Syndrome for Characterizing Immune Responses against Pathogens.

Authors:  Catalina Lopez-Saucedo; Rodolfo Bernal-Reynaga; Jesus Zayas-Jahuey; Silvia Galindo-Gomez; Mineko Shibayama; Carlos Garcia-Galvez; Sergio Estrada-Parra; Teresa Estrada-Garcia
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

8.  Age-related variations in the in vitro bactericidal activity of human sera against Pseudomonas aeruginosa.

Authors:  Akram Khan; Isfahan Tauseef; Bibi Aalia; Muhammad Azam Khan; Sadia Akbar; Nighat Sultana; Kashif S Haleem
Journal:  Cent Eur J Immunol       Date:  2018-03-30       Impact factor: 2.085

9.  Emergence of Carbapenem Non-susceptible Campylobacter coli after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia.

Authors:  Hideharu Hagiya; Keigo Kimura; Isao Nishi; Hisao Yoshida; Norihisa Yamamoto; Yukihiro Akeda; Kazunori Tomono
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

10.  Atypical presentation of Good syndrome: acute hepatitis from hepatitis B virus reactivation.

Authors:  Yi Wye Lai; Teck-Choon Tan
Journal:  Asia Pac Allergy       Date:  2020-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.